WO2003048359A1 - Markers for sugar/lipid metabolic disorders and utilization thereof - Google Patents

Markers for sugar/lipid metabolic disorders and utilization thereof Download PDF

Info

Publication number
WO2003048359A1
WO2003048359A1 PCT/JP2002/012793 JP0212793W WO03048359A1 WO 2003048359 A1 WO2003048359 A1 WO 2003048359A1 JP 0212793 W JP0212793 W JP 0212793W WO 03048359 A1 WO03048359 A1 WO 03048359A1
Authority
WO
WIPO (PCT)
Prior art keywords
sugar
metabolic disorders
lipid metabolic
markers
utilization
Prior art date
Application number
PCT/JP2002/012793
Other languages
French (fr)
Japanese (ja)
Inventor
Junji Ichihara
Eiji Sugaru
Mutsuo Taiji
Original Assignee
Sumitomo Pharmaceuticals Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Company, Limited filed Critical Sumitomo Pharmaceuticals Company, Limited
Priority to AU2002361078A priority Critical patent/AU2002361078A1/en
Publication of WO2003048359A1 publication Critical patent/WO2003048359A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11025—Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

It is intended to provide polynucleotides having at least 15 consecutive bases in the base sequence of MLTK gene and/or polynucleotides complementary to these polynucleotides, as disease markers for sugar/lipid metabolic disorders; a method of detecting sugar/lipid metabolic disorders with the use of these disease markers; and a method of screening a drug useful in ameliorating these diseases.
PCT/JP2002/012793 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof WO2003048359A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002361078A AU2002361078A1 (en) 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001371420 2001-12-05
JP2001-371420 2001-12-05
JP2002-41542 2002-02-19
JP2002041542A JP2003230388A (en) 2001-12-05 2002-02-19 Disease marker of sugar-lipid dysbolism and utilization thereof

Publications (1)

Publication Number Publication Date
WO2003048359A1 true WO2003048359A1 (en) 2003-06-12

Family

ID=26624888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/012793 WO2003048359A1 (en) 2001-12-05 2002-12-05 Markers for sugar/lipid metabolic disorders and utilization thereof

Country Status (3)

Country Link
JP (1) JP2003230388A (en)
AU (1) AU2002361078A1 (en)
WO (1) WO2003048359A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118833A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4749861B2 (en) * 2003-08-28 2011-08-17 大日本住友製薬株式会社 Preventive or therapeutic agent for inflammatory bowel disease containing anti-CD81 antibody as active ingredient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735370A1 (en) * 1995-03-28 1996-10-02 Takeda Chemical Industries, Ltd. Method for assaying map kinase
WO1998053050A2 (en) * 1997-05-21 1998-11-26 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of serine/threonine kinases
WO2000014212A1 (en) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Novel protein kinase molecules and uses therefor
WO2001012670A1 (en) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. Tgf-beta receptor polynucleotides, polypeptides, and antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0735370A1 (en) * 1995-03-28 1996-10-02 Takeda Chemical Industries, Ltd. Method for assaying map kinase
WO1998053050A2 (en) * 1997-05-21 1998-11-26 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of serine/threonine kinases
WO2000014212A1 (en) * 1998-09-09 2000-03-16 Millennium Pharmaceuticals, Inc. Novel protein kinase molecules and uses therefor
WO2001012670A1 (en) * 1999-08-13 2001-02-22 Human Genome Sciences, Inc. Tgf-beta receptor polynucleotides, polypeptides, and antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ISAMU GOTOH ET AL.: "Identification and characterization of a novel MAP kinase kinase kinase, MLTK", THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, pages 4276 - 4286, XP002965828 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118833A2 (en) * 2004-06-01 2005-12-15 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
WO2005118833A3 (en) * 2004-06-01 2006-05-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)

Also Published As

Publication number Publication date
JP2003230388A (en) 2003-08-19
AU2002361078A1 (en) 2003-06-17

Similar Documents

Publication Publication Date Title
USD482368S1 (en) Display for touchscreen of a computer monitor
USD483074S1 (en) Display apparatus
USD489717S1 (en) Tablet personal computer
EP2821085A3 (en) RNA interference for the treatment of gain-of-function disorders
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
USD504923S1 (en) Dumbbell
WO2002072604A3 (en) Genes and polymorphisms associated with cardiovascular disease and their use
AU2002336759A1 (en) Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
CA2451519A1 (en) Tablet comprising cetirizine and pseudoephedrine
AU2002319717A1 (en) Mutant nurr1 gene in parkinson's disease
WO2003057874A1 (en) Disease markers for renal diseaes and utilization thereof
USD475841S1 (en) Boot
WO2003048359A1 (en) Markers for sugar/lipid metabolic disorders and utilization thereof
USD489996S1 (en) Clock
WO2003027284A1 (en) Bone metablic disease markers and utilization thereof
USD491427S1 (en) Universal camshaft retainer
USD477316S1 (en) Computer
USD480907S1 (en) Roaster
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
USD517613S1 (en) Playing card
WO2001077149A3 (en) Regulation of human cyslt2-like gpcr protein
WO1998039429A3 (en) Compositions for treatment of disorders involving programmed cell death
USD491621S1 (en) Firing pin block
AU2002341044A1 (en) Methods for detecting parkinson's disease
USD471198S1 (en) Computer mouse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase